ISET

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Medical Devices, Health, Clinical Trials, Medical Supplies, Sale, Aortoiliac occlusive disease, DCB, Cell, Sundance, ISET, Master of Medicine, Freedom, Restenosis, Safety, PHD, Ambient occlusion, PP, MS, Pharmaceutical industry, MBBS, Anesthetic, FRACS

The session will be held on Wednesday, November 15th, at the 50th annual VEITH Symposium in New York, New York.

Key Points: 
  • The session will be held on Wednesday, November 15th, at the 50th annual VEITH Symposium in New York, New York.
  • Professor Varcoe previously presented SWING Trial 12-month data on January 18th at the 35th Annual International Symposium on Endovascular Therapy (ISET) conference.
  • Sirolimus, a potent anti-inflammatory and anti-proliferative compound, has been used successfully in coronary drug-eluting stents.
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.

IS32LT3138, 18-Channel Current-Sink LED Driver for Dynamic Automotive Exterior Light Animation

Retrieved on: 
Monday, July 10, 2023
MCU, Communication, ISSI, Light-emitting diode, Failure, CRC, Cyclic redundancy check, ISO, Temperature, EMC, PWM, NTC, ISET, UART, LED, PCB, Polychlorinated biphenyl, Printed circuit board

The IS32LT3138 is an 18 channel, current sink LED driver that allows up to 64 devices to be cascaded, for a total of 1152 individually controlled channels.

Key Points: 
  • The IS32LT3138 is an 18 channel, current sink LED driver that allows up to 64 devices to be cascaded, for a total of 1152 individually controlled channels.
  • “The automotive industry is requesting unique and complex light animation features to establish brand identity and provide the car buyer with personalization capabilities,” said Ven Shan VP of Lumissil Marketing.
  • “The design challenge has been managing many driver ICs to independently control the large number of LED pixels required for smooth and uninterrupted lighting effects that encircle a vehicle.
  • A 4.2V output supply connected to an NTC temperature sensor helps mitigate LED board thermals by lowering the LED current if the temperature rises.

Microbot Medical Expands its Geographic Presence to South America with the Addition of Francisco C. Carnevale, MD, PhD, FSIR to its Scientific Advisory Board

Retrieved on: 
Monday, February 27, 2023
Society, Vision-guided robot systems, Interventional radiology, Doctor of Philosophy, Urology, MD, RSNA, University, PAE, GEST, SAB, Harvard University, KOL, WCIO, Prostatic artery embolization, Cardiovascular and Interventional Radiological Society of Europe, Society of Interventional Radiology, Research, SIR, BPH, Patient, ISET, WAIS, CIRSE, Carnevale, Book, Hospital, ESR, Physician, Medical imaging, EU

HINGHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), today announced that it has expanded its global presence to South America with the addition of Francisco C. Carnevale, MD, PhD, FSIR, becoming the latest key opinion leader (KOL) to join the Company’s Scientific Advisory Board (SAB).

Key Points: 
  • HINGHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), today announced that it has expanded its global presence to South America with the addition of Francisco C. Carnevale, MD, PhD, FSIR, becoming the latest key opinion leader (KOL) to join the Company’s Scientific Advisory Board (SAB).
  • Dr. Carnevale, a vascular and interventional radiologist based in Sao Paolo, Brazil, is the Chief of the Vascular Interventional Radiology Section at Hospital das Clinicas - University of Sao Paulo Medical School Hospital (HC-FMUSP).
  • “Dr.
  • For a complete list and background on the members of Microbot’s SAB, please use this link

ISET celebrates 35th anniversary meeting with nearly 1,000 registrants, record-breaking number of research submissions, sold out Exhibit Hall

Retrieved on: 
Thursday, January 19, 2023
Convention, PE, National Primate Research Exhibition Hall, University of Pennsylvania, SVM, Baptist Health, SIR, MVP, Florida International University, University, Record, Interventional radiology, Division, Movement, 2021 Essex County Council election, Society for Vascular Surgery, Society, FIU Herbert Wertheim College of Medicine, SVS, Centre for the Advancement of Sustainable Medical Innovation, FACC, Faculty, HMP, Society of Interventional Radiology, Town hall, ISET, Organization, Partnership, CME, Radiology, Society for Vascular Medicine, Degenerative disease, Research, International Symposium on Endovascular Therapy, Amputation, CLI, CNE, PAD, Health, Pharmaceutical industry, Medicine, Dentistry, MD

MALVERN, Pa., Jan. 19, 2023 /PRNewswire-PRWeb/ -- For its 35th annual gathering, HMP Global's International Symposium on Endovascular Therapy (ISET) received a record-breaking amount of research submissions, welcomed nearly 1,000 registrants from around the globe, and hosted more than 40 companies in its sold-out Exhibit Hall, solidifying its position as the premier arena for pioneering and practical endovascular education.

Key Points: 
  • "From the group that pioneered live case education, ISET has grown tremendously since the first meeting 35 years ago," Katzen said.
  • "Now as the leading meeting in endovascular therapy, ISET brings together a multidisciplinary faculty and audience to discuss groundbreaking techniques, implement change, and improve patient care.
  • All abstracts underwent blind peer review for quality of research, educational or scientific content, logical presentation, and impact on healthcare.
  • Cutting-edge research e-posters were displayed on multimedia screens in the poster area of the Exhibit Hall at ISET, and late-breaking data was presented at the first major endovascular meeting in 2023.

Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference

Retrieved on: 
Thursday, January 19, 2023
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, MS, CDR, SCB-125, ISET, PHD, Death, Sirolimus, Patient, Master of Medicine, International Symposium on Endovascular Therapy, PAD, SCB, Sundance, Pharmaceutical industry, FRACS, MBBS

The SWING trial is a first-in-human feasibility study of the Company’s Sundance™ SCB.

Key Points: 
  • The SWING trial is a first-in-human feasibility study of the Company’s Sundance™ SCB.
  • At ISET, SWING co-lead investigator Professor Ramon Varcoe, MBBS, MS, FRACS, PHD, MMed (ClinEpi), reinforced key findings from the SWING trial.
  • Rather than using encapsulation, the Sundance™ SCB delivers drug to target tissue via a coating of stable crystalline sirolimus with a proprietary excipient on the balloon surface, a method the Company describes as Crystalline Drug Release, or CDR.
  • When inflated, the Sundance™ SCB transfers this crystalline drug form to the vessel wall, whereupon the crystalized drug itself serves as the drug depot in a process that eliminates the need for a polymer depot.

Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18

Retrieved on: 
Monday, January 16, 2023
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, FRANZCR, Cell, MS, Auckland City Hospital, Aortoiliac occlusive disease, Safety, SCB Park Plaza, ISET, PHD, ONZM, Master of Medicine, Sale, DCB, Restenosis, International Symposium on Endovascular Therapy, Pharmaceutical industry, FRACS, Bachelor of Medicine, Bachelor of Surgery, MBBS, Anesthetic

The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida.

Key Points: 
  • The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida.
  • Professor Varcoe will also discuss the differentiated capabilities of the Surmodics crystalline drug release platform for sirolimus-coated balloons (SCBs) in connection with 12-month data from the SWING trial.
  • Professor Varcoe recently presented SWING Trial 12-month data on Nov. 16 at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium).
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.

2023 International Symposium on Endovascular Therapy (ISET) strengthened by partnerships with leading organizations SIR, SVM, SVS

Retrieved on: 
Thursday, November 17, 2022
Society for Vascular Medicine, Convention, Q&A, Osteopathic medicine in the United States, Interventional radiology, DRS, Professor, Health, International Symposium on Endovascular Therapy, Florida International University, Founding, FACS, Partnership, University, Associate Director of National Intelligence and Chief Information Officer, Michigan State University College of Osteopathic Medicine, Surgery, Baptist Health, Chair, FSVM, ISET, FIU Herbert Wertheim College of Medicine, Assistant professor, Society for Vascular Surgery, Society of Interventional Radiology, George Washington University, RPVI, SVM, Centre for the Advancement of Sustainable Medical Innovation, Affiliation, MPH, Society, Organization, University of South Florida College of Medicine, Baptists, SIR, SVS, FACC, Dentistry, Medical imaging, Medicine, Radiology, MD

MALVERN, Pa., Nov. 17, 2022 /PRNewswire-PRWeb/ -- HMP Global's 2023 International Symposium on Endovascular Therapy (ISET) is strengthening its position as the premier meeting for pioneering and practical endovascular education through continued endorsement from the Society of Interventional Radiology (SIR), continued partnership with the Society of Vascular Medicine (SVM), who co-developed the "Essentials of Endovascular Therapy" pre-symposium, and a recently added educational partnership with the Society of Vascular Surgery (SVS), who collaborated on overall programming and provided two new vascular surgery Course Directors to the expert lineup this year .

Key Points: 
  • Now in its 35th year, ISET will take place in person January 16-19, 2023 in Miami Beach and will feature a bold scientific program covering the complete landscape of endovascular therapy practice and challenges.
  • The meeting is an arena to connect interventional radiologists, vascular surgeons, interventional cardiologists, and their teams.
  • "These partnerships add exponential value to the meeting by incorporating multidisciplinary expertise and additional innovative practice strategies into the symposium sessions," Katzen said.
  • "We are excited that experts from our partnering organizations are among our course directors guiding the agenda for ISET.

HMP Global Solidifies Position as World's Largest Producer of Cardiovascular Events and Education with Acquisition of Renowned Western Atrial Fibrillation Symposium

Retrieved on: 
Monday, June 13, 2022
Argentum, Conference, Amputation, Cardiology, VRTX, AF, International Symposium on Endovascular Therapy, ISET, Symposium, Faculty, Marketing, CEO, Partnership, Elderly care, EMS, Diagnosis, Learning, AMP, EMT, Digital journalism, Physician, Health, Patient, Acquisition, Electrophysiology, SMASH, Internal medicine, Education, Research, News, Disease, Senior living, Practitioner, Growth, Student, CIO, Clinical trial, CLI, Atrial fibrillation, Evolution, SAWC, LINC, Pharmaceutical industry, Medicine, Silver, MD, Psychotherapy

MALVERN, Pa., June 13, 2022 /PRNewswire-PRWeb/ -- HMP Global, the world's largest healthcare event and education company, today announced it has entered into a partnership to produce the Western Atrial Fibrillation Symposium, the premier educational event focused exclusively on atrial fibrillation (AF).

Key Points: 
  • Now in its 16th year, the Western Atrial Fibrillation Symposium takes place annually in February in Park City, Utah.
  • "Sixteen years ago, we created the Western Atrial Fibrillation Symposium with the vision of offering a robust outlet to advance an integrated approach to understanding and treating atrial fibrillation," said Nassir Marrouche, MD, internationally renowned electrophysiologist, and symposium director.
  • Beginning in 2023, the Western Atrial Fibrillation Symposium will benefit from the strength and expertise HMP Global brings in medical meeting management, education, and marketing.
  • The partnership with Western Atrial Fibrillation Symposium continues a period of accelerated growth for HMP Global.

InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial

Retrieved on: 
Tuesday, January 18, 2022
Forward-looking statement, Xi, Conference, Stroke, Clinical trial, CAD, SEC, TEL, Stenosis, GLOBE, Micronet, U.S. Securities and Exchange Commission, International Symposium on Endovascular Therapy, Nasdaq, Industry, NSPR, Company, EPS, Sale, ISET, Trademark dilution, Ballad, Compliance, Security (finance), Risk, Principal investigator, Pharmaceutical industry, Medical imaging

We are extremely grateful to have been selected and approved for a Live Case Presentation at this years ISET Conference demonstrating the advantages of CGuard, said Marvin Slosman, Chief Executive Officer of InspireMD.

Key Points: 
  • We are extremely grateful to have been selected and approved for a Live Case Presentation at this years ISET Conference demonstrating the advantages of CGuard, said Marvin Slosman, Chief Executive Officer of InspireMD.
  • Our team at Ballad Health have completed 40 patient enrollments in the C-Guardians IDE trial.
  • We are pleased with our device performance experience thus far, said Dr. Chris Metzger, trial Principal Investigator.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests

Retrieved on: 
Thursday, December 9, 2021
Blood, Risk, Liquid biopsy, Neoplasm, Technology, Mortality, Cancer, CTC, DNA, Patient, Adoption, ISET, Bias, Diagnosis, Prostate cancer, Acute myeloid leukemia, AI, Algorithm, Medical imaging

The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests.

Key Points: 
  • The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests.
  • saidDavide Brchot, Deputy CEO, "Liquid biopsy has the potential to revolutionize cancer diagnostics and markedly lower mortality from cancer through early detection.
  • Rarecells, Inc.is a healthcare company focused on the development and commercialization of non-invasive Early Cancer Detection tests.
  • This approach is believed to be a significant advancement in the highly sensitive non-invasive detection of cancer's signals providing a powerful tool for early cancer detection through the identification of the first circulating cancer cells.